Thymic epithelial tumors (TETs) have been characterized at the molecular level through bioptic sections and cell lines. Despite these advances, there is a need for a more thorough characterization of the thymic stroma in thymoma, particularly because of the diversity of cell types that populate the tumor and the absence of a healthy thymic counterpart. Recent work on healthy pediatric thymi – both in vitro and at the single-cell level – now sets the stage for new studies on their neoplastic counterparts. Furthermore, general transcription factor IIi (GTF2I), a thymoma-specific oncogene, as well as some of its SNPs, are increasingly associated with autoimmune disease, a significant feature of thymomas. We summarize recent discoveries in the field and discuss the development of new targeted therapies.

Thymic stroma and TFII-I: towards new targeted therapies / P.G. Manti, S. Trattaro, D. Castaldi, M. Pezzali, L. Spaggiari, G. Testa. - In: TRENDS IN MOLECULAR MEDICINE. - ISSN 1471-4914. - 28:1(2022 Jan), pp. 67-78. [10.1016/j.molmed.2021.10.008]

Thymic stroma and TFII-I: towards new targeted therapies

P.G. Manti
Primo
;
S. Trattaro
Secondo
;
D. Castaldi;M. Pezzali;L. Spaggiari
Penultimo
;
G. Testa
Ultimo
2022

Abstract

Thymic epithelial tumors (TETs) have been characterized at the molecular level through bioptic sections and cell lines. Despite these advances, there is a need for a more thorough characterization of the thymic stroma in thymoma, particularly because of the diversity of cell types that populate the tumor and the absence of a healthy thymic counterpart. Recent work on healthy pediatric thymi – both in vitro and at the single-cell level – now sets the stage for new studies on their neoplastic counterparts. Furthermore, general transcription factor IIi (GTF2I), a thymoma-specific oncogene, as well as some of its SNPs, are increasingly associated with autoimmune disease, a significant feature of thymomas. We summarize recent discoveries in the field and discuss the development of new targeted therapies.
autoimmunity; targeted therapy; TFII-I; thymic epithelial tumors (TETs); thymic stroma;
Settore BIO/11 - Biologia Molecolare
gen-2022
2-dic-2021
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/891415
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact